# First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer

> **NCT01723475** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 47 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **BIOLOGICAL:** BAY2010112
- **BIOLOGICAL:** BAY2010112

## Key facts

- **NCT ID:** NCT01723475
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-02
- **Primary completion:** 2018-07-18
- **Final completion:** 2018-09-26
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2019-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01723475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01723475, "First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01723475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*